Abstract
The development of proteomic technologies that display a wide variety of antigenic structures has led to the identification of autoantibodies to cancer-derived tumor antigens. These autoantibodies have been detected in sera from patients with multiple cancer types, and are being evaluated as biomarkers for early cancer detection. It is not known whether these antibodies also contribute to active immune surveillance or even tumorigenicity of developing tumors. Here, we review which tumor antigen-specific antibodies are prognostic biomarkers of cancer outcome, and emerging proteomic methods for the isolation and cloning of these antibodies for potential molecular diagnostics and therapeutics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 577-589 |
| Number of pages | 13 |
| Journal | Expert Review of Proteomics |
| Volume | 8 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2011 |
Keywords
- autoantibodies
- cancer
- clinical outcome
- function
- human monoclonal antibodies
- prognosis
- prognostic
- recurrence
- survival
- therapeutic antibodies
- tumor antigens
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology